{"entity":{"id":"candiolo","kind":"institution","name":"Istituto di Candiolo IRCCS (FPO)","aka":["Candiolo Cancer Institute","Fondazione Piemontese per l'Oncologia","IRCCS Candiolo","INOC - Istituto Nazionale Oncologico Candiolo","Istituto Nazionale Oncologico Candiolo"],"tldr":"Piedmont's cancer institute near Turin, a world reference for colorectal cancer genomics, patient-derived xenografts and MET biology.","summary":"The Candiolo Cancer Institute is a private not-for-profit IRCCS run by the Fondazione Piemontese per l'Oncologia with the University of Turin. Paolo Comoglio's laboratory discovered and characterised the MET oncogene, Livio Trusolino and Andrea Bertotti built a large colorectal cancer patient-derived xenograft platform ('xenopatients') that identified HER2 amplification as a target and led to the HERACLES trial of trastuzumab plus lapatinib, and Alberto Bardelli's group pioneered liquid biopsy tracking of resistance to anti-EGFR therapy. The hospital provides surgery, radiotherapy, medical oncology and a phase 1 unit, and hosts a large biobank and a molecular tumour board for the Piedmont network.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.fpoircc.it/en/"},{"label":"Research","url":"https://www.fpoircc.it/en/research/"}],"tags":[],"related":[],"cancers":["colorectal","gastric","breast-her2-positive"],"sections":["targeted-therapy","diagnostics"],"technologies":["pdx-models","liquid-biopsy","kinase-inhibitors","monoclonal-antibody"],"targets":["met","her2","egfr","kras"],"drugs":["trastuzumab"],"companies":[],"institutions":[],"pathways":[],"terms":["ctdna","resistance"],"trials":[],"people":["anna-sapino","alberto-bardelli","andrea-agnelli"],"bottlenecks":["b-resistance","b-preclinical-models"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Candiolo","country":"IT","lat":44.958,"lng":7.593,"institutionType":"cancer-center","website":"https://www.fpoircc.it/en/","university":"Università degli Studi di Torino","programs":["Colorectal cancer genomics and xenopatients","MET oncogene biology","Liquid biopsy and resistance","Phase 1 trials"]},"route":"/institutions/candiolo/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"pdx-models","kind":"technology","name":"Patient-derived xenografts","route":"/technologies/pdx-models/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"},{"id":"met","kind":"target","name":"MET","route":"/targets/met/"}],"drug":[{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"resistance","kind":"term","name":"Drug resistance (primary and acquired)","route":"/terms/resistance/"}],"person":[{"id":"alberto-bardelli","kind":"person","name":"Alberto Bardelli","route":"/people/alberto-bardelli/"},{"id":"andrea-agnelli","kind":"person","name":"Andrea Agnelli","route":"/people/andrea-agnelli/"},{"id":"anna-sapino","kind":"person","name":"Anna Sapino","route":"/people/anna-sapino/"}],"bottleneck":[{"id":"b-resistance","kind":"bottleneck","name":"Acquired resistance to every therapy","route":"/bottlenecks/b-resistance/"},{"id":"b-preclinical-models","kind":"bottleneck","name":"Lab models that fail to predict what happens in patients","route":"/bottlenecks/b-preclinical-models/"}],"paper":[{"id":"paper-bertotti-xenopatients-her2-cetuximab-resistant-colorectal-cancer-discov-2011","kind":"paper","name":"A molecularly annotated platform of patient-derived xenografts identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer","route":"/key-papers/paper-bertotti-xenopatients-her2-cetuximab-resistant-colorectal-cancer-discov-2011/"},{"id":"paper-valtorta-her2-scoring-colorectal-heracles-mod-pathol-2015","kind":"paper","name":"Assessment of a HER2 scoring system for colorectal cancer: results from a validation study","route":"/key-papers/paper-valtorta-her2-scoring-colorectal-heracles-mod-pathol-2015/"},{"id":"paper-sartore-bianchi-heracles-trastuzumab-lapatinib-lancet-oncol-2016","kind":"paper","name":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES)","route":"/key-papers/paper-sartore-bianchi-heracles-trastuzumab-lapatinib-lancet-oncol-2016/"},{"id":"paper-misale-kras-acquired-resistance-anti-egfr-colorectal-nature-2012","kind":"paper","name":"Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer","route":"/key-papers/paper-misale-kras-acquired-resistance-anti-egfr-colorectal-nature-2012/"},{"id":"paper-isella-stromal-contribution-colorectal-transcriptome-nat-genet-2015","kind":"paper","name":"Stromal contribution to the colorectal cancer transcriptome","route":"/key-papers/paper-isella-stromal-contribution-colorectal-transcriptome-nat-genet-2015/"}]}}